Latest News for: mbx

Edit

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Nasdaq Globe Newswire 17 Mar 2025
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 ... .
Edit

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (Form 8-K) (MBX Biosciences Inc)

Public Technologies 17 Mar 2025
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights ... MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025 ... MBX 4291IND filing on track for Q2 2025.
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (MBX Biosciences Inc)

Public Technologies 17 Mar 2025
MBX Biosciences, Inc ... MBX Biosciences, Inc ... MBX Biosciences, Inc ... MBX Biosciences, Inc ... MBX Biosciences, Inc ... Fourth Amended and Restated Certificate of Incorporation of MBX Biosciences, Inc ... Amended and Restated Bylaws of MBX Biosciences, Inc.
Edit

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) (MBX Biosciences Inc)

Public Technologies 17 Mar 2025
• advance the development of our lead product candidates, canvuparatide, MBX 1416 and MBX 4291, and future product candidates; ... MBX 2109, MBX 1416 and MBX 4291 are Licensed Products under the IURTC License Agreement.
Edit

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Nasdaq Globe Newswire 03 Mar 2025
AvailTM trial exceeded enrollment target; topline results expected in Q3 2025. AvailTM trial exceeded enrollment target; topline results expected in Q3 2025 ... .
  • 1
×